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Abstract: This article reviews the molecular biology of the inter-
action of histamine with its H1-receptor and describes the concept
that H1-antihistamines are not receptor antagonists but are inverse
agonists i.e. they produce the opposite effect on the receptor to hista-
mine. It then discourages the use of first-generation H1-antihistamines
in clinical practice today for two main reasons. First, they are less
effective than second generation H1-antihistamines. Second, they
have unwanted side effects, particularly central nervous system and
anti-cholinergic effects, and have the potential for causing severe
toxic reactions which are not shared by second-generation H1-
antihistamines. There are many efficacious and safe second-gener-
ation H1-antihistamines on the market for the treatment of allergic
disease. Of the three drugs highlighted in this review, levocetirizine
and fexofenadine are the most efficacious in humans in vivo.
However, levocetirizine may cause somnolence in susceptible indi-
viduals while fexofenadine has a relatively short duration of action
requiring twice daily administration for full all round daily protec-
tion. While desloratadine is less efficacious, it has the advantages of
rarely causing somnolence and having a long duration of action.
Lastly, all H1-antihistamines have anti-inflammatory effects but it
requires regular daily dosing rather than dosing ‘on-demand’ for this
effect to be clinically demonstrable.
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It is now more than a century since the discovery of hista-mine,1 more than 70 years since the pioneering studies of
Anne Marie Staub and Daniel Bovet led to the discovery of
the first antihistamine2 and more than 60 years since the
introduction into the clinic of antergan in 1942,3 followed by
diphenhydramine in 19454 and chlorpheniramine, bromphe-
niramine, and promethazine later the same decade. Medicinal
chemistry was very different in those days compared with the
present day as elegantly described by Emanuel in his review
entitled “Histamine and the antiallergic antihistamines: a
history of their discoveries.”5 The usual way of testing novel
compounds was to measure histamine-induced contractions
of pieces of muscle from experimental animals, usually
guinea-pig intestine, suspended in an organ bath. Candidate
antihistaminic compounds were primarily modifications of
those synthesized as cholinergic antagonists and are from
diverse chemical entities, ethanolamines, ethylene diamines,
alkylamines, piperazines, piperidines, and phenothiazines. It
is hardly surprising, therefore, that these first-generation an-
tihistamines had poor receptor selectivity and significant
unwanted side effects.
During this time, knowledge of the nature and diversity
of receptors was rudimentary to say the least and it was only
several decades later that the existence of more than one
species of histamine receptor was discovered. This review
will concentrate on the histamine H1-receptor. Further details
on the biology and clinical functions of histamine H2-, H3-,
and H4-receptors are the subject of a separate review.6
THE HISTAMINE H1-RECEPTOR
The human histamine H1-receptor is a member of the
superfamily of G-protein coupled receptors. This superfamily
represents at least 500 individual membrane proteins that
share a common structural motif of 7 transmembrane -he-
lical segments7,8 (Fig. 1A). The histamine H1-receptor gene
encodes a 487 amino acid protein with a molecular mass of
55.8 kDa.9,10 The absence of introns in the H1-receptor gene
indicates that only a single receptor protein is transcribed
with no splice variants.10
The histamine H1-receptor, like other G-protein cou-
pled receptors, may be viewed as “cellular switches,” which
exist as an equilibrium between the inactive or “off” state and
the active or “on” state.11 In the case of the histamine
H1-receptor, histamine cross-links sites on transmembrane
domains III and V to stabilize the receptor in its active
conformation, thus causing the equilibrium to swing to the on
position12 (Fig. 1B). H1-antihistamines, which are not struc-
turally related to histamine, do not antagonize the binding of
histamine but bind to different sites on the receptor to
produce the opposite effect. For example, cetirizine cross-
links sites on transmembrane domains IV and VI to stabilize
the receptor in the inactive state and swing the equilibrium to
the off position13 (Fig. 1C). Thus, H1-antihistamines are not
receptor antagonists but are inverse agonists in that they
produce the opposite effect on the receptor to histamine.14
Consequently, the preferred term to define these drugs is
“H1-antihistamines” rather than “histamine antagonists.”
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FIRST-GENERATION H1-ANTIHISTAMINES
Because first-generation H1-antihistamines derive from
the same chemical stem from which cholinergic muscarinic
antagonists, tranquilizers, antipsychotics, and antihyperten-
sive agents were also developed, they have poor receptor
selectivity and often interact with receptors of other biolog-
ically active amines causing antimuscarinic, anti–-adrener-
gic, and antiserotonin effects. But perhaps their greatest
drawback is their ability to cross the blood-brain barrier and
interfere with histaminergic transmission. Histamine is an
important neuromediator in the human brain which contains
approximately 64,000 histamine-producing neurones, located
in the tuberomamillary nucleus. When activated, these neu-
rones stimulate H1-receptors in all of the major parts of the
cerebrum, cerebellum, posterior pituitary, and spinal cord15
where they increase arousal in the circadian sleep/wake cycle,
reinforce learning and memory, and have roles in fluid bal-
ance, suppression of feeding, control of body temperature,
control of the cardiovascular system, and mediation of stress-
triggered release of adrenocorticotrophic hormone and -
endorphin from the pituitary gland.16 It is not surprising then
that antihistamines crossing the blood-brain barrier interfere
with all of these processes.
Physiologically, the release of histamine during the day
causes arousal whereas its decreased production at night
results in a passive reduction of the arousal response. When
taken during the day, first-generation H1-antihistamines, even
in the manufacturers’ recommended doses, frequently cause
daytime somnolence, sedation, drowsiness, fatigue, and im-
paired concentration and memory.17,18 When taken at night,
first-generation H1-antihistamines increase the latency to the
onset of rapid eye movement sleep and reduce the duration of
rapid eye movement sleep.19–21 The residual effects of poor
sleep, including impairment of attention, vigilance, working
memory, and sensory-motor performance, are still present the
next morning.20,22 The detrimental central nervous system
effects of first-generation H1-antihistamines on learning and
examination performance in children and on impairment of
the ability of adults to work, drive, and fly aircraft have been
reviewed in detail in a recent review.23
The use of first-generation H1-antihistamines in young
children has recently been brought into question. In the
United States, reports of serious and often life-threatening
adverse events of promethazine in children led to a “boxed
warning” being added in 2004 to the labeling of prometha-
zine. The warning included a contraindication for use in
children younger than 2 years and a strengthened warning
with regard to use in children 2 years of age or older.24 In
February 2009, the Medicines and Healthcare products Reg-
ulatory Agency (MHRA) in the United Kingdom25 advised
that cough and cold remedies containing certain ingredients,
including first-generation H1-antihistamines, should no lon-
ger be used in children younger than 6 years because the
balance of benefit and risks has not been shown to be
favorable. Reports submitted to regulators stated that more
than 3000 people have reported adverse reactions to these
drugs and that diphenhydramine and chlorpheniramine were
mentioned in reports of 27 and 11 deaths, respectively.25
SECOND-GENERATION H1-ANTIHISTAMINES
A major advance in antihistamine development oc-
curred in the 1980s with the introduction of second-genera-
tion H1-antihistamines,26 which are minimally sedating or
nonsedating because of their limited penetration of the blood-
brain barrier. In addition, these drugs are highly selective for
the histamine H1-receptor and have no anticholinergic effects.
When choosing an H1-antihistamine, patients seek at-
tributes that include good efficacy, a rapid onset of action, a
long duration of action, and freedom from unwanted effects.
Although some of these attributes may be predicted from
preclinical and pharmacokinetic studies, it is only in the
clinical environment that they may be definitively estab-
lished.
Efficacy
The efficacy of an H1-antihistamine is determined by 2
factors: the affinity of the drug for H1-receptors (absolute
potency) and the concentration of the drug at the sites of the
H1-receptors.
The affinity of an H1-antihistamine for H1-receptors is
determined in preclinical studies. Desloratadine is the most
potent antihistamine (Ki 0.4 nM) followed by levocetirizine
(Ki 3 nM) and fexofenadine (Ki 10 nM) (the lower the
concentration, the higher potency). Although these are often
considered to be fixed values, they may be influenced by
temperature and pH, and therefore, they can differ in physi-
ologic and pathologic conditions. For example, in inflamma-
tion the pH of the tissues is reduced27 from 7.4 to 5.8, leading
to a 2- to 5-fold increase in the affinity of fexofenadine and
FIGURE 1. A, Diagram of a histamine H1-receptor in a
membrane showing the 7 transmembrane domains. Hista-
mine stimulates the receptor after its penetration into the
central core of the receptor. B, A surface view of an acti-
vated receptor with histamine linking domains III and V. C,
A surface view of an inactive receptor with cetirizine linking
domains IV and VI.
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levocetirizine for H1-receptors but no change in the affinity of
desloratadine.28
As shown in Figure 2, histamine receptors are situated
on the cellular membranes of cells, including vascular and
airways smooth muscle, mucous glands, and sensory nerves,
all of which are surrounded by the extracellular fluid. Many
factors affect concentration of free drug in this compartment.
First, it must be absorbed into the systemic circulation after
oral dosage with a tablet or capsule. Most H1-antihistamines
are well absorbed, the exception being fexofenadine, which
has a very variable absorption because of the influence of
active transporting proteins as described later.29,30 Second is
the extent of plasma binding which, with H1-antihistamines,
is high, varying from 65% with desloratadine to 90% for
levocetirizine.31 Third, and probably most influential, is the
apparent volume of distribution which determines the plasma
concentration of a drug after complete body distribution. The
apparent volume of distribution is limited for levocetirizine
(0.4 L/kg), larger for fexofenadine (5.4–5.8 L/kg), and par-
ticularly large for desloratadine (49 L/kg).32 The large
apparent volume of distribution of desloratadine is largely
due to its extensive intracellular uptake. In the study of
Gillard and colleagues,31 the 4-hour plasma concentrations of
levocetirizine, desloratadine, and fexofenadine are 28, 1, and
174 nM, respectively.
Because data on the concentrations of H1-antihista-
mines in relevant extracellular fluids is generally lacking, the
best indirect estimate of efficacy is obtained by calculating
receptor occupancy from knowledge of absolute potency and
peak drug concentrations in the plasma, usually at 4 hours
after a single oral dose using the following equation.31
Receptor occupancy (%)  Bmax 
L
L  Ki
where Bmax is the maximal number of binding sites (set to
100%), L the concentration of free drug in the plasma, and Ki
the equilibrium inhibition constant ('absolute potency).
Thus, the calculation of receptor occupancy after single
oral doses of drug shows values of 95%, 90%, and 71% for
fexofenadine, levocetirizine, and desloratadine, respectively,
indicating that they are all very effective H1-antihistamines.
Although receptor occupancy for these drugs appears to
correlate with pharmacodynamic activity in skin wheal and
flare studies and with efficacy in allergen challenge chamber
studies,33,34 are the differences relevant in clinical practice?
Studies in allergic rhinitis suggest that the above 3 drugs are
of similar effectiveness.35,36 However, in chronic urticaria in
which local histamine concentrations are high, the differences
do seem to be important. For example, in head to head studies
in this condition levocetirizine appears significantly more
effective than desloratadine.37,38
Speed of Onset of Action
The speed of onset of action of a drug is often equated
to the rate of its oral absorption. However, this is not strictly
correct as seen from Figure 3, which shows the inhibition of
the histamine-induced flare response (indicative of the pre-
vention by levocetirizine of sensory neurone stimulation in
the extravascular space) plotted against the concentration of
free drug in the plasma. In this study in children,39 plasma
concentrations of drug are near maximum by 30 minutes and
yet it takes an additional 1.5 hours for the drug to diffuse into
the extravascular space to produce a maximal clinical effect.
In adults, the maximal inhibition of the flare response is
usually 4 hours for levocetirizine, fexofenadine, and deslo-
ratadine40–42 but may be longer for drugs, such as loratadine
and ebastine, which require metabolism to produce their
active moiety.40
Duration of Action
Figure 3 also shows that the duration of action of
levocetirizine in inhibiting the histamine-induced flare re-
sponse is also much longer than would be predicted from a
knowledge of its plasma concentration.39 This is presumably
due to “trapping” of the drug by its strong and long-lasting
binding to histamine H1-receptors.13 Although less active in
the wheal and flare test, desloratadine has a similarly long
duration of action.41 However, the duration of action of
fexofenadine, calculated in the study of Purohit et al43 as the
time for the wheal to be inhibited by at least 70%, is less
prolonged, being 8.5 hours for 120 mg fexofenadine com-
FIGURE 2. Diagrammatic representation of the absorption
of an H1-antihistamine. Histamine H1-receptors are indicated
by stars on the surface of cells and a sensory nerve in the
extravascular space.
FIGURE 3. Hysteresis loop of the inhibition of the hista-
mine-induced flare response plotted against the plasma con-
centration of unbound levocetirizine after administration of a
single 5-mg dose to children. Redrawn from Ref. 39.
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pared with 19 hours for cetirizine. The primary reason for the
shorter duration of action of fexofenadine is that it is actively
secreted into the intestine and urine.44
Anti-Inflammatory Effects
Although the majority of research into H1-antihista-
mines has focused on the histamine-dependent early phase
symptoms of the allergic response, it is now becoming clear
that these drugs have anti-inflammatory effects. This follows
the observation by Bakker and colleagues45 that histamine
can activate NF-B, a transcription factor involved in the
synthesis of many pro-inflammatory cytokines and adhesion
molecules involved in the initiation and maintenance of
allergic inflammation. The anti-inflammatory effects of H1-
antihistamines, which is a class effect mediated through the
H1-receptor, are summarized in Ref.14 The clinical implica-
tions of this lie in the ability of H1-antihistamines to reduce
nasal congestion and hyper-reactivity,36 which result from the
sensitization of sensory neurones in the nose by allergic
inflammation.46 However, as nasal congestion is more slowly
relieved than other nasal symptoms,47 continuous rather than
on demand therapy with antihistamines is required for its
treatment.48
Elimination
The metabolism and elimination of H1-antihistamines
have been extensively reviewed elsewhere32,49 and will be
only briefly summarized here. Cetirizine and levocetirizine
are not metabolized and are excreted primarily unchanged in
the urine.32 Desloratadine undergoes extensive metabolism in
the liver. Although this gives the potential for drug-drug
interactions, no significant interactions have been reported.49
Fexofenadine, which is also minimally metabolized, is ex-
creted primarily in the feces after its active secretion into the
intestine under the influence of active drug–transporting mol-
ecules.49 This gives the potential for interactions with agents
such as grapefruit juice and St Johns Wort, which inhibit
these transporters. Although plasma concentrations of fexo-
fenadine may be increased by these agents, no significant
resulting adverse reactions have been reported.49
Unwanted Effects
Somnolence
A major reason for the reduced penetration of second-
generation H1-antihistamines into the brain is because their
translocation across the blood-brain barrier is under the control
of active transporter proteins, of which the ATP-dependent
efflux pump, P-glycoprotein, is the best known.50,51 It also
became apparent that antihistamines differ in their substrate
specificity for P-glycoprotein, fexofenadine being a particularly
good substrate.52 In the brain, the H1-receptor occupancy of
fexofenadine assessed using positron emission tomography
scanning is negligible, 0.1%, and, in psychomotor tests, fexo-
fenadine is not significantly different from placebo.53 Further-
more, fexofenadine has been shown to be devoid of central
nervous effects even at supraclinical doses, up to 360 mg.54
Although fexofenadine is devoid of CNS effects, other
second-generation H1-antihistamines many still penetrate the
brain to a small extent where they have the potential to cause
some degree of drowsiness or somnolence, particularly when
used in higher doses. For example, positron emission tomog-
raphy scanning of the human brain has shown that single oral
doses of 10 and 20 mg of cetirizine caused 12.5 and 25.2%
occupancy of the H1-receptors in prefrontal and cingulate
cortices, respectively.55 These results would explain the re-
peated clinical findings that the incidence of drowsiness or
fatigue is greater with cetirizine than with placebo.56–59
Recent publications have suggested that, at manufacturer’s
recommended doses, levocetirizine is less sedating than ce-
tirizine60 and desloratadine causes negligible somno-
lence.49,61 However, it should be pointed out that “mean
results” do not reveal everything as some patients may show
considerable somnolence whereas others are unaffected.
Cardiotoxicity
The propensity of astemizole and terfenadine to block
the IKr current, to prolong the QT interval, and to potentially
cause serious polymorphic ventricular arrhythmias such as
torsades de pointes is well documented.14,62 These 2 drugs are
no longer approved by regulatory agencies in most countries.
In addition, some first-generation H1-antihistamines, such as
promethazine,63 brompheniramine,64 and diphenhydramine,65
may also be associated with a prolonged QTc and cardiac
arrhythmias when taken in large doses or overdoses. No
clinically significant cardiac effects have been reported for
the second-generation H1-antihistamines loratadine, fexofe-
nadine, mizolastine, ebastine, azelastine, cetirizine, deslorata-
dine, and levocetirizine.66–69
CONCLUSIONS
In conclusion, the use of first-generation H1-antihista-
mines should be discouraged in clinical practice today for 2
main reasons. First, they are less effective than second-
generation H1-antihistamines.17,70,71 Second, they have un-
wanted side effects and the potential for causing severe toxic
reactions which are not shared by second-generation H1-
antihistamines. With regard to second-generation H1-antihis-
tamines, there are many efficacious and safe drugs on the
market for the treatment of allergic disease. Of the 3 drugs
highlighted in this review, levocetirizine and fexofenadine
are the most potent in humans in vivo. However, levocetiriz-
ine may cause somnolence in susceptible individuals whereas
fexofenadine has a relatively short duration of action and may
be required to be given twice daily for all-round daily protection.
Although desloratadine is less potent, it has the advantages of
rarely causing somnolence and having a long duration of action.
Lastly, all H1-antihistamines have anti-inflammatory effects but
it requires regular daily dosing rather than dosing “on demand”
for this action to be clinically demonstrable.
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